Featured Articles

  1. Gov. Gretchen Whitmer Announces West Contract Manufacturing Expansion Creating 110 Jobs In West Michigan 1/31/2022

    Gov. Gretchen Whitmer joined the Michigan Economic Development Corporation (MEDC) today to announce that West Pharmaceutical Services, Inc., through its subsidiary West Contract Manufacturing (West), plans to expand in the city of Walker, where it will create up to 110 jobs for Michigan workers.

  2. West Announces Landmark Collaboration With Corning In Pharmaceutical Injectable Drug Delivery 1/26/2022

    The exclusive long-term supply and development agreement includes a multimillion-dollar capital and R&D investment in Corning to enable advanced drug containment and delivery system solutions.

  3. West Pharmaceuticals And MEDX Xelerator Sign Strategic Collaboration 11/23/2021

    The agreement is focused on identifying and developing early-stage medical technology innovation. Under the terms of the accord, West will provide funding for joint venture creations at the incubator and will have the option to further invest in these same projects, alongside the incubator, if the projects mature into portfolio companies.

  4. West Launches New Vial2Bag Advanced™ 20mm Admixture Device 10/22/2020

    West Pharmaceutical Services, Inc. (NYSE: WST), West Pharmaceutical Services, Inc. (West) is pleased to announce FDA 510(k) clearance and launch of its Vial2Bag Advanced™ 20mm Admixture Device.

  5. Holistic QbD: A Key To Improved Profitability And Sustained Competitive Advantage With Sterile Pharmaceutical Products 8/9/2012

    Pharmaceutical companies are faced with assuring that new quality and compliance paradigms can be met while facilitating profitability to continue adequate business reinvestment. By Fran DeGrazio, Vice President, Global Research and Development, Pharmaceutical Packaging Systems West Pharmaceutical Services, Inc.

  6. The Importance Of Strategic Alliance Partners

    Complex drug delivery systems require teamwork between biopharmaceutical companies and their drug delivery technology partners to develop innovative platforms for patient use. These alliance partners must ensure self-administered therapies are safe, easy to use, and effective. 

  7. Understanding Risks Of Biologic Drugs And Injectable Drug-Device Combination Products

    As the benefits of delivering biologic drugs as part of a combination product platform are realized, this self-administration trend will continue to grow. From a regulatory perspective, the use of a risk-based approach is foundational.

  8. Addressing Glass Particulates In Injectable Drug Formulations

    Learn how a new vial design that is capable of reducing the propensity for glass particulate generation on filling lines is enabling a significant, positive impact on product quality and safety.

  9. Create An Effective Risk Management Program

    Drug-device combination products are rapidly increasing in use, based on their numerous benefits. This article is a review of achieving performance and regulatory compliance for their successful development and commercialization.

  10. How To Address Challenges In Oncology Drug Containment

    Drug product containment systems comprising Daikyo Crystal Zenith® cyclic olefin polymer (COP) vials, matched with NovaPure® stoppers, offer container closure integrity (CCI) performance that has been quantified for oxygen and carbon dioxide, and they have excellent system performance.